Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women.
Antimicrob Agents Chemother
; 55(3): 1120-2, 2011 Mar.
Article
en En
| MEDLINE
| ID: mdl-21173188
ABSTRACT
We report darunavir, ritonavir, and etravirine pharmacokinetics in cervicovaginal fluid and blood plasma for women from the Gender, Race and Clinical Experience (GRACE) study. Eight women received darunavir-ritonavir (600/100 mg) twice daily (b.i.d.); two also received etravirine (200 mg) b.i.d. Week 4 paired blood plasma and cervicovaginal fluid samples were collected over 12 h. Darunavir and etravirine cervicovaginal fluid exposures were higher than blood plasma exposures; ritonavir cervicovaginal fluid exposure was lower than blood plasma exposure. The high exposures of darunavir and etravirine in cervicovaginal fluid warrant further evaluation of these drugs for use in HIV-1 prevention.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Piridazinas
/
Sulfonamidas
/
Infecciones por VIH
/
Ritonavir
Tipo de estudio:
Clinical_trials
Límite:
Adult
/
Female
/
Humans
/
Middle aged
Idioma:
En
Año:
2011
Tipo del documento:
Article